Specifically, CD19 CAR-T cells generated from NKG2C+ CD8+ T cells exhibited superior tumor killing, persistence, and significantly reduced cytokine release syndrome compared to conventional CAR-T cells (83). Here, CD8A is linked to neoplasm.